Sugi Predict

Sugi Predict / Compounds / SCHEMBL3435648

SCHEMBL3435648

SCHEMBL3435648

O=C(O)c1csc(N2CCCC2)n1

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ PTGER1 P34995 7/20 0.56
▸ SMN1; SMN2 Q16637 3/20 0.49
▸ AR P10275 1/20 0.49
▸ TP53 P04637 1/20 0.49
▸ ALOX15 P16050 1/20 0.49
▸ HSD17B10 Q99714 1/20 0.49
▸ OGA O60502 1/20 0.48
▸ ALDH1A1 P00352 2/20 0.48
▸ L3MBTL1 Q9Y468 2/20 0.48
▸ MEN1 O00255 1/20 0.48
▸ LMNA P02545 1/20 0.48
▸ POLB P06746 1/20 0.48
▸ HPGD P15428 1/20 0.48
▸ BLM P54132 1/20 0.48
▸ KMT2A Q03164 1/20 0.48
▸ ESR2 Q92731 1/20 0.48
▸ LDHA P00338 1/20 0.46
▸ CSNK2A2 P19784 1/20 0.46
▸ CSNK2B P67870 1/20 0.46
▸ CSNK2A1 P68400 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3435678 0.98 PTGER1 (0.59) PTGER1SMN1; SMN2ARTP53ALOX15
SCHEMBL3435711 0.86 AR (0.53) PTGER1SMN1; SMN2AROGAALDH1A1
SCHEMBL10429396 0.85 CHEK1 (0.49) PTGER1OGALDHA
SCHEMBL420357 0.85 AR (0.54) SMN1; SMN2ARHSD17B10OGAALDH1A1
SCHEMBL3435755 0.83 OGA (0.45) PTGER1SMN1; SMN2OGAALDH1A1LDHA
Hydrochloric Acid SCHEMBL2583821 0.83 CHEK1 (0.48) PTGER1OGALDHA
SCHEMBL2078959 0.83 PTGER1 (0.48) PTGER1SMN1; SMN2OGAL3MBTL1MEN1
SCHEMBL28141436 0.83 HRH3 (0.50) PTGER1SMN1; SMN2ARTP53ALOX15
SCHEMBL13162578 0.82 OGA (0.46) PTGER1SMN1; SMN2OGAALDH1A1L3MBTL1
SCHEMBL2080793 0.82 OGA (0.44) PTGER1SMN1; SMN2OGAALDH1A1LDHA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 40 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11834452-B2 CXCR7 antagonists CHEMOCENTRYX, INC. (US) 2023-12-05 — — US disclosed
US-11834452-B2 CXCR7 antagonists CHEMOCENTRYX, INC. (US) 2023-12-05 — — US disclosed
US-11834452-B2 CXCR7 antagonists CHEMOCENTRYX, INC. (US) 2023-12-05 — — US disclosed
US-11807644-B2 Methods and compounds for restoring mutant p53 function PMV PHARMACEUTICALS, INC. (US) 2023-11-07 — — US disclosed
US-11807644-B2 Methods and compounds for restoring mutant p53 function PMV PHARMACEUTICALS, INC. (US) 2023-11-07 — — US disclosed
US-20230002403-A1 METHODS AND COMPOUNDS FOR RESTORING MUTANT p53 FUNCTION PMV PHARMACEUTICALS, INC. 2023-01-05 — — US disclosed
US-20220127272-A1 CXCR7 ANTAGONISTS CHEMOCENTRYX, INC. 2022-04-28 — — US disclosed
US-20220127272-A1 CXCR7 ANTAGONISTS CHEMOCENTRYX, INC. 2022-04-28 — — US disclosed
WO-2021231474-A1 METHODS AND COMPOUNDS FOR RESTORING MUTANT p53 FUNCTION PMV PHARMACEUTICALS, INC. (US) 2021-11-18 — — WO disclosed
US-11059825-B2 CXCR7 antagonists CHEMOCENTRYX, INC. (US) 2021-07-13 — — US disclosed
EP-2925745-A1 CXCR7 ANTAGONISTS ChemoCentryx, Inc. (US) 2015-10-07 — — EP disclosed
WO-2014085490-A1 CXCR7 ANTAGONISTS CHEMOCENTRYX, INC. (US) 2014-06-05 — — WO disclosed
US-20140154179-A1 CXCR7 ANTAGONISTS CHEMOCENTRYX, INC. (US) 2014-06-05 — — US disclosed
US-20140154179-A1 CXCR7 ANTAGONISTS CHEMOCENTRYX, INC. (US) 2014-06-05 — — US disclosed
WO-2014085490-A1 CXCR7 ANTAGONISTS CHEMOCENTRYX, INC. (US) 2014-06-05 — — WO disclosed
US-20140154179-A1 CXCR7 ANTAGONISTS CHEMOCENTRYX, INC. (US) 2014-06-05 — — US disclosed
US-8163746-B2 Azolecarboxamide derivative ASTELLAS PHARMA INC. (JP) 2012-04-24 — — US disclosed
US-8163746-B2 Azolecarboxamide derivative ASTELLAS PHARMA INC. (JP) 2012-04-24 — — US disclosed
US-20090286766-A1 AZOLECARBOXAMIDE DERIVATIVE ASTELLAS PHARMA INC. (JP) 2009-11-19 — — US disclosed
US-20090286766-A1 AZOLECARBOXAMIDE DERIVATIVE ASTELLAS PHARMA INC. (JP) 2009-11-19 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230002403-A1 METHODS AND COMPOUNDS FOR RESTORING MUTANT p53 FUNCTION TP53, TP53BP1, HRAS PTGER1 4571/4885SMN1; SMN2 3494/4885AR 2682/4885
US-11807644-B2 Methods and compounds for restoring mutant p53 function TP53, TP53BP1, HRAS PTGER1 4571/4885SMN1; SMN2 3494/4885AR 2682/4885
US-11059825-B2 CXCR7 antagonists CXCR1, CXCR5, CCR7 PTGER1 419/4885SMN1; SMN2 4258/4885AR 449/4885
US-11834452-B2 CXCR7 antagonists CXCR1, CXCR5, CCR7 PTGER1 419/4885SMN1; SMN2 4258/4885AR 449/4885
US-20140154179-A1 CXCR7 ANTAGONISTS CXCR1, CXCR5, CCR7 PTGER1 419/4885SMN1; SMN2 4258/4885AR 449/4885
US-20090286766-A1 AZOLECARBOXAMIDE DERIVATIVE GPR17, NTRK1, TRPV1 PTGER1 1115/4885SMN1; SMN2 3601/4885AR 16/4885
US-20220127272-A1 CXCR7 ANTAGONISTS CXCR1, CXCR5, CCR7 PTGER1 419/4885SMN1; SMN2 4258/4885AR 449/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.